$116 Million is the total value of Opus Point Partners Management, LLC's 65 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LGND | Exit | LIGAND PHARMACEUTICALS INC | $0 | – | -1,519 | -100.0% | -0.19% | – |
| Q | Exit | QUINTILES IMS HOLDINGS INC | $0 | – | -5,413 | -100.0% | -0.46% | – |
| LABU | Exit | DIREXION SHS ETF TRsp biotch bl new | $0 | – | -16,002 | -100.0% | -1.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.